With the reform of EU pharmaceutical legislation moving towards publication, companies have a window to prepare. A phased approach avoids both premature spending and last-minute scrambling.
Step one: map your portfolio
Classify products by status: authorised, under assessment, planned for submission before late 2028, or planned after. Published analyses indicate that procedures submitted before the relevant application dates are expected to be completed under current rules, so submission timing now has strategic value.
Step two: identify early obligations
- Shortage duties. Notification and prevention plans are reported to apply around six months after entry into force.
- Supply requests. Member State requests to place products on the market are reported to follow around one year after entry into force.
- Early provisions. Vouchers, sandboxes and critical medicine measures apply from entry into force.
Step three: review internal capability
Regulatory affairs, pharmacovigilance, quality and supply teams will each need updated procedures. Governance for shortage notification, launch commitments and lifecycle submissions is a good starting point.
Step four: watch the detail
Implementing and delegated acts will determine many operational details. National transposition of the Directive may also vary, so Greek requirements should be monitored separately.
A note on certainty
Dates in public commentary are estimates tied to Official Journal publication. Verify against the published text before committing resources.
How PQRA helps
PQRA offers a structured gap assessment against the reform, helps prioritise investment and builds a monitoring routine for guidance, implementing acts and Greek transposition.


No responses yet